Role of Ready to Drink Nutritional Formula (Protison Enriched with ω-3 FA and BCAA) Supplemented by Nasogastric Tube Feeding in Various Cancer Patients: A Clinical Trial
Background and Objective: Cancer patients often encounter various health issues like malnutrition, cachexia and fatigue during or after chemotherapy. Hence, they need balanced nutritional support (nutraceuticals and dietary supplements) to maintain optimal health status. Current clinical trial was designed to examine the impact of balanced nutritional formula-ProtisonTM cancer nutritional formula (PCNF; enriched with ω-3 FA, fibers, BCAA and micro-nutrients), in various cancer patient by checking calorie intake and overall health status. Materials and Methods: Totally 42 cancer patients with poor nutritional status under nasogastric (NG) tube feeding was recruited and administered with the commercial nutritional formula (PCNF; 237 mL/Pack) for 5-6 times/day via bolus NG tube feeding for 12 weeks. Results: Subjects administered with PCNF showed a significant increase (p<0.001) in calorie intake and increased body weight, BMI. Also, the levels of total proteins, pre-albumin and transferrin were also significantly increased (p<0.007) in PCNF supplemented patients. Moreover, PCNF fed cancer subjects showed normal range of various biochemical parameters like glycemic indices, lipid profile and various biochemical markers with improved nutritional status. Conclusion: Taking together that PCNF tube-fed cancer patients showed better health status (lower the risk of malnutrition and cachexia) by improving body weight, BMI, protein and pre-albumin without any adverse effects. PDFFulltextXMLReferencesCitation
How to cite this article
Sheng-Chang Lin, Hsien-Chun Tseng, Hui-Fang Chiu, Zhuang Shuru, Ming-Yi Fan, Hsin-Yi Lu, Yi-Chun Han, You-Cheng Shen, Kamesh Venkatakrishnan and Chin-Kun Wang, 2021. Role of Ready to Drink Nutritional Formula (Protison Enriched with ω-3 FA and BCAA) Supplemented by Nasogastric Tube Feeding in Various Cancer Patients: A Clinical Trial. International Journal of Pharmacology, 17: 113-121.